Hepatic Encephalopathy Therapeutics Pipeline Review, H1 2015 offers “Hepatic Encephalopathy – Pipeline Review, H1 2015”global research report on its store.

This report provides comprehensive information on the therapeutic development for Hepatic Encephalopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic Encephalopathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report is available at .

Scope of The Report:

  • The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hepatic Encephalopathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hepatic Encephalopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hepatic Encephalopathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to Buy This Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Order a copy of this report at .

Table of Content for “Hepatic Encephalopathy – Pipeline Review, H1 2015” research report includes:

Hepatic Encephalopathy Overview 6

Therapeutics Development 7

Pipeline Products for Hepatic Encephalopathy - Overview 7

Pipeline Products for Hepatic Encephalopathy - Comparative Analysis 8

Hepatic Encephalopathy - Therapeutics under Development by Companies 9

Hepatic Encephalopathy - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Hepatic Encephalopathy - Products under Development by Companies 13

Hepatic Encephalopathy - Companies Involved in Therapeutics Development 14

Alfa Wassermann S.p.A 14

Hyperion Therapeutics, Inc. 15

Ocera Therapeutics, Inc. 16

Umecrine Cognition AB 17

Hepatic Encephalopathy - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 26

CVXL-0060 - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

glycerol phenylbutyrate - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

ornithine phenylacetate - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

rifaximin - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

THDP-17 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Hepatic Encephalopathy - Recent Pipeline Updates 35

Hepatic Encephalopathy - Dormant Projects 41

Hepatic Encephalopathy - Product Development Milestones 42

Featured News & Press Releases 42

Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin 42

Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada 42

Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology 43

Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550 43

Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin 44

Jan 08, 2014: Ocera Therapeutics Announces Enrollment of the First Patient in a Phase IIb Study for Treatment of Acute Hepatic Encephalopathy 44

Nov 01, 2013: Salix Pharmaceuticals Outlines Data Presentations at American Association for the Study of Liver Diseases Annual Meeting 45

Sep 09, 2013: Scottish Medicines Consortium Accepts TARGAXAN 550 46

May 24, 2013: Norgine Announces PBAC Approval For Xifaxan 550mg In Prevention Of Recurrence Of Hepatic Encephalopathy 46

May 17, 2013: Salix Pharma To Present Data On Rifaximin At Digestive Disease Week 2013 47

Priced at US $2000 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. ( ).